Fig. 1From: Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue(A) Proteomics workflow for FFPE clinical samples analyzed by FAIMS-PRM. (B) The range of RASG12C and wild-type RAS protein expression in NSCLC FFPE tumor tissues (n = 32). RASG12C was only quantified above the FAIMS-PRM assay LLOQ (dashed line, 46 amol/µg) in tumors known to have the KRASG12C mutationBack to article page